Amgen Stock Analysis (NASDAQ:AMGN)

Add to My Stocks
$155.01 $0.42 (0.27%) AMGN stock closing price May 26, 2017 (Closing)
Watch Robo Advisor Video of AMGN Stock Analysis
Amgen
Updated on : May 26, 2017
previous close
AMGN 155 (0%)
S&P 500 2415.8 (0%)
Closing Price On: May 26, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q1
$billion
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
7.6%
Operating Profit
Operating Margin:
43.5%
Sector Average:
1.1%
5 Quarter Net Profit
Net Margins
2017-Q1
%
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt:
34.09B
Debt/Equity Ratio:
 1.11
Compared to the industry
Cash Flow
Operating cash flow:
$2.39B
Net Income:
$2.07B
Dividend Yield
AMGN dividend yield:
2.68%
PROS      CONS
Operating Margins
Net Margins
ROIC
ROE
FCF Margin
PE Valuation
Long Term Growth
High Debt Burden
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
AMGN PS :
5
Industry PS :
4.6
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
36.3%
Return on Equity:
26.3%
Free Cash Flow Margin:
40.6%
Double Tap To Exit Full Screen
0:00
/

Amgen Analysis Video

1044 5 3 1

View Amgen stock analysis video. This is our AMGN analyst opinion covering the buy and sell arguments for AMGN stock.

Amgen, Inc. Stock Rating (4.5/5)

Our Amgen stock opinion is based on fundamentals of the company. This Amgen stock analysis is based on latest Q1 earnings for 2017. The stock price analysis takes into account a company's valuation metrics.

Should you buy AMGN stock?

  • The TTM operating margin was good at 43.5% for Amgen.
  • Net margins came in at average 34.4% for Amgen over the last twelve months.
  • AMGN stock is trading at an earnings multiple of 13 which is better than the industry average of 22.5.
  • Amgen generates a high return on invested capital of 36.3%.
  • Amgen has a good Return On Equity (ROE) of 26.3%.
  • Amgen has a healthy FCF (Free Cash Flow) margin of 40.6%.

Should you sell AMGN stock?

  • Over the last 5 years, the company registered a poor revenue growth of 7.6%.
  • With a debt/equity ratio of  1.11, Amgen is highly leveraged in comparison to Medical peers.

Comments on this video and Amgen stock

tavern123 on Amgen stock analysis ($148.69)
bullish
The stock is relatively cheap. It deserves another look. If "what goes up, must come down", then "what is down, should go up"!
reply